Travelers With Cutaneous Leishmaniasis Cured Without Systemic Therapy

Guidelines recommend wound care and/or local therapy as first-line treatment for cutaneous leishmaniasis. An analysis of a referral treatment program in 135 travelers showed that this approach was feasible in 62% of patients, with positive outcome in 83% of evaluable patient

Demographic, clinical and antibody characteristics of patients with digital ulcers in systemic sclerosis: data from the DUO Registry

OBJECTIVES: The Digital Ulcers Outcome (DUO) Registry was designed to describe the clinical and antibody characteristics, disease course and outcomes of patients with digital ulcers associated with systemic sclerosis (SSc). METHODS: The DUO Registry is a European, prospective, multicentre, observational, registry of SSc patients with ongoing digital ulcer disease, irrespective of treatment regimen. Data collected included demographics, SSc duration, SSc subset, internal organ manifestations, autoantibodies, previous and ongoing interventions and complications related to digital ulcers. RESULTS: Up to 19 November 2010 a total of 2439 patients had enrolled into the registry. Most were classified as either limited cutaneous SSc (lcSSc; 52.2%) or diffuse cutaneous SSc (dcSSc; 36.9%). Digital ulcers developed earlier in patients with dcSSc compared with lcSSc. Almost all patients (95.7%) tested positive for antinuclear antibodies, 45.2% for anti-scleroderma-70 and 43.6% for anticentromere antibodies (ACA). The first digital ulcer in the anti-scleroderma-70-positive patient cohort occurred approximately 5 years earlier than the ACA-positive patient group. CONCLUSIONS: This study provides data from a large cohort of SSc patients with a history of digital ulcers. The early occurrence and high frequency of digital ulcer complications are especially seen in patients with dcSSc and/or anti-scleroderma-70 antibodies

Methotrexate efficacy and tolerance in plaque psoriasis. A prospective real-life multicentre study in France

International audienc

Errance médicale des patients atteints d’hidradénite suppurée : un problème majeur et persistant. Étude « R-ENS Verneuil »

International audienceObjectiveTo provide physicians with an understanding of the factors behind significant delays in the diagnosis of hidradenitis suppurativa (HS) in France.Patients and methodsThis prospective multicentre national study conducted from October 2015 to March 2016 included all patients consulting for HS. Patient data were collected by means of a standardized questionnaire. Univariate and multivariate analyses were conducted to collect factors associated with a significant time to diagnosis of at least 5.5 years, defined as the period between the onset of initial clinical signs and the time of formal diagnosis.ResultsThe 16 participating centres enrolled 312 patients (62% women), of average age 35 years. The average age at onset of HS was 22 years. Before formal diagnosis by a dermatologist (64% of cases), 170 (54%), 114 (37%) and 45 (15%) patients had previously consulted at least 3, 5 and 10 general physicians, respectively. The average time between the initial clinical signs of HS, the first dermatology visit and the definitive diagnosis was 6.2 and 8.4 years, respectively. Active smoking (OR adjusted 1.85; P = 0.027) and disease onset at a younger age (adjusted OR 0.92; P < 0.001) were both associated with significant delays in diagnosis.ConclusionThese results emphasized misdiagnosis among HS patients but did not evidence any association between either sociodemographic or economic characteristics and the existence of significant times to diagnosis.ObjectifL’objectif principal de cette étude était d’analyser les facteurs associés à l’existence d’un délai diagnostique significatif chez les patients atteints d’hidradénite suppurée (HS) en France.Malades et méthodesCette étude nationale prospective multicentrique réalisée d’octobre 2015 à mars 2016 incluait tous les patients consultant pour une HS. Les données concernant les patients étaient recueillies à l’aide d’un questionnaire standardisé. Des analyses univariée et multivariée ont été effectuées afin de recueillir les facteurs associés à un délai diagnostique significatif, défini comme un délai d’au moins 5,5 ans entre les premiers signes de la maladie et son diagnostic formel.RésultatsLes 16 centres ont inclus 312 patients (62 % de femmes) d’âge moyen 35 ans. L’âge moyen de début de l’HS était de 22 ans. Respectivement 170 (54 %), 114 (37 %) et 45 (15 %) patients avaient consulté au moins 3, 5 et 10 médecins avant le diagnostic formel, qui était posé par un dermatologue dans 64 % des cas. Les premiers signes d’HS étaient apparus en moyenne 6,2 ans avant la première consultation de dermatologie et 8,4 ans avant le diagnostic. Un tabagisme actif (Odd Ratio (OR) ajusté 1,85; p = 0,027) et un début des signes à un âge plus précoce (OR ajusté 0,92; p < 0,001) étaient associés à un délai diagnostique significatif.ConclusionCes résultats soulignent l’errance médicale des patients atteints d’HS, mais ne montrent pas d’association entre les caractéristiques sociodémographiques ou économiques des patients et l’existence d’un délai diagnostique significatif